Interview with Olivier Daubry, General Manager, Celgene France
In only four years Celgene has introduced a number of important products in the French market and is now seen as a…
Celgene France
Last updated: 13.02.2014
Address: 16/18, Rue du Quatre Septembre
75002 Paris
,France
Tel: +33 1 53 42 43 00
Company description
Celgene is a multinational biopharmaceutical company committed to improving the lives of patients worldwide.
Celgene seeks to deliver truly innovative and life-changing drugs for our patients. It’s mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
Thanks to the establishment of its structure in France, a 100% subsidiary of Celgene Corporation, Celgene France ensures its presence on the French health market. Celgene France, besides the marketing of drugs, will establish many clinical trials of new molecules derived from the R&D of Celgene. These, of course, will be conducted in cooperation with the most recognized French medical institutions.
Products and services
There are numerous clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin’s lymphoma (NHL), glioblastoma, and ovarian, pancreatic and prostate cancer.
Global Products
ISTODAX® (romidepsin) for injection
REVLIMID® (lenalidomide)
THALOMID® (thalidomide)
VIDAZA® (azacitidine for injection)
Services
LifebankUSA (placental and cord blood banking)
Interviews
Related
France / Valneva: Small, but Poised for COVID-19 Vaccine Success
While Big Pharma companies like Pfizer, Janssen and AstraZeneca, have grabbed the headlines over the past year for…
France / ‘Humiliation’ & the Sanofi-Pfizer Vaccine Deal; AntiVax Struggles; Servier’s Neurology Push
The latest from French pharma where Sanofi has inked a deal to produce 125 million doses of Pfizer’s COVID-19…
France / Mid-2021 for Sanofi COVID-19 Vaccine; 1 Million Domestic Cases; Ipsen Growth
A roundup of the latest stories from French pharma, including the progress of Sanofi’s COVID-19 vaccine, how…
News Roundup / French Pharma August 2020
A roundup of some of the latest from French pharma, including Sanofi’s bumper Prinicipia deal, how Unither’s…
M&A / Sanofi Buys Principia for USD 3.7 Billion as Part of Specialty Pivot
Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in…
Sanofi / Thomas Triomphe Appointed Executive Vice President of Vaccines Unit
With former head David Loew moving to the CEO position at Ipsen, Sanofi appointed French national Thomas Triomphe…
Mid-Cap Strategies / LFB USA CEO Optimistic on Hemophilia Launches Amid COVID Crisis
French firm LFB is targeting the lucrative US market with its hemophilia products and recently received two FDA…
Sanofi / USD 679 Million Investment in French Vaccine Manufacturing
French pharma giant Sanofi is pivoting its focus to invest more heavily in vaccines with a plan to invest USD 679…
Ipsen / New CEO as David Loew Makes Switch From Sanofi Pasteur
David Loew, formerly executive vice president of Sanofi Pasteur, Sanofi’s vaccines division, was appointed…
Europe / A New Approach to Health Crises in France & Germany
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would…
COVID-19 Vaccine / Sanofi CEO Paul Hudson Commits to "Bring a Solution to Everybody, Everywhere"
In a recent interview with Financial Times, Sanofi CEO Paul Hudson set out to clarify some recent comments that the…
Coronavirus / GSK & Sanofi’s Unprecedented COVID-19 Vaccine Collaboration
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are…
